Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 9, 2012, Pages

  Wouters, E F M ^a   Bredenbroker D ^b   Teichmann, P ^b   Brose, M ^b   Rabe, K F ^c,d,e   Fabbri, L M ^f   Goke B ^g  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Nycomed A Takeda Company   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

^d KRANKENHAUS GROSSHANSDORF   (Germany)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^g UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; FATTY ACID; GLUCAGON; GLUCOSE; GLYCEROL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; PLACEBO; ROFLUMILAST;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEROL BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; METABOLIC PARAMETERS; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TREATMENT RESPONSE;

ADULT; AGED; AMINOPYRIDINES; AREA UNDER CURVE; BENZAMIDES; BLOOD GLUCOSE; BODY WEIGHT; C-PEPTIDE; CYCLOPROPANES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FASTING; FATTY ACIDS, NONESTERIFIED; FEMALE; GLUCAGON; GLUCOSE; GLYCEROL; HEMOGLOBIN A, GLYCOSYLATED; HOMEOSTASIS; HUMANS; INSULIN; MALE; MIDDLE AGED; PHOSPHODIESTERASE 4 INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SAMPLE SIZE;

EID: 84866148535     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-2886     Document Type: Article

References (14)

1. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J 2007 Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176:532-555 (Pubitemid 47403272)
2. Rabe KF 2011 Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol 163:53-67
3. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ 2009 Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374:685-694
4. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF 2009 Roflumilast in moderate-tosevere chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 374:695-703
5. 1998 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837-853
6. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W 1986 Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29:46-52 (Pubitemid 16162741)
7. Holst JJ 2007 The physiology of glucagon-like peptide 1. Physiol Rev 87:1409-1439 (Pubitemid 350041474)
8. Shah P, Vella A, Basu A, Basu R, Schwenk WF, RizzaRA2000 Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 85:4053-4059 (Pubitemid 32055352)
9. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, Holst JJ 2001 Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86:3717-3723 (Pubitemid 32755966)
10. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD 2004 Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27:2628-2635 (Pubitemid 39441462)
11. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L 2009 Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallelgroup, multinational, open-label trial (LEAD-6). Lancet 374:39-47
12. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD 2005 Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28:1092-1100 (Pubitemid 40616618)
13. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B 2009 Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373:473-481
14. Groop LC, Bonadonna RC, DelPrato S, Ratheiser K, Zyck K, Ferrannini E, DeFronzo RA 1989 Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest 84:205-213 (Pubitemid 19170111)